| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 10/19/2026 | 3. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (1) | 11/01/2028 | Common Shares | 4,892 | $35.59 | D | |
| Stock Option (Right to Buy) | (2) | 10/22/2029 | Common Shares | 1,395 | $39 | D | |
| Stock Option (Right to Buy) | (3) | 03/10/2030 | Common Shares | 2,805 | $44.67 | D | |
| Stock Option (Right to Buy) | (4) | 10/05/2030 | Common Shares | 1,800 | $86.75 | D | |
| Stock Option (Right to Buy) | (5) | 03/11/2031 | Common Shares | 4,522 | $133.88 | D | |
| Stock Option (Right to Buy) | (6) | 10/15/2031 | Common Shares | 1,966 | $97 | D | |
| Stock Option (Right to Buy) | (7) | 02/18/2032 | Common Shares | 3,840 | $58.29 | D | |
| Stock Option (Right to Buy) | (8) | 10/07/2032 | Common Shares | 2,366 | $61.65 | D | |
| Stock Option (Right to Buy) | (9) | 03/10/2033 | Common Shares | 8,431 | $43.22 | D | |
| Stock Option (Right to Buy) | (10) | 10/13/2033 | Common Shares | 3,766 | $44.31 | D | |
| Stock Option (Right to Buy) | (11) | 03/20/2034 | Common Shares | 9,039 | $72.94 | D | |
| Stock Option ( Right to Buy) | (12) | 10/16/2034 | Common Shares | 3,766 | $49 | D | |
| Stock Option (Right to Buy) | (13) | 03/14/2035 | Common Shares | 18,734 | $42.12 | D | |
| Stock Option (Right to Buy) | (14) | 10/03/2035 | Common Shares | 6,944 | $67.74 | D | |
| Stock Option (Right to Buy) | (15) | 03/20/2036 | Common Shares | 14,874 | $46.24 | D | |
| Restricted Stock Units | (16) | (16) | Common Shares | 1,300 | (17) | D | |
| Restricted Stock Units | (18) | (18) | Common Shares | 3,390 | (17) | D | |
| Restricted Stock Units | (19) | (19) | Common Shares | 15,000 | (17) | D | |
| Restricted Stock Units | (20) | (20) | Common Shares | 8,437 | (17) | D | |
| Restricted Stock Units | (21) | (21) | Common Shares | 12,000 | (17) | D | |
| Restricted Stock Units | (22) | (22) | Common Shares | 15,000 | (17) | D | |
| Restricted Stock Units | (23) | (23) | Common Shares | 10,000 | (17) | D | |
| Explanation of Responses: |
| 1. This option was granted on November 1, 2018 with respect to 10,000 Common Shares. 25% of the shares vested on November 1, 2019, with the remaining shares vested in 48 equal monthly installments thereafter. |
| 2. This option was granted on October 22, 2019 with respect to 1,716 Common Shares. 100% of the shares vested in 48 equal monthly installments, with the first installment vested on November 22, 2019. |
| 3. This option was granted on March 10, 2020 with respect to 3,960 Common Shares. 100% of the shares vested in 48 equal monthly installments, with the first installment vested on April 10, 2020. |
| 4. This option was granted on October 5, 2020 with respect to 1,800 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 5, 2020. |
| 5. This option was granted on March 11, 2021 with respect to 4,522 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 11, 2021. |
| 6. This option was granted on October 15, 2021 with respect to 1,966 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 15, 2021. |
| 7. This option was granted on February 18, 2022 with respect to 3,840 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on March 18, 2022. |
| 8. This option was granted on October 7, 2022 with respect to 2,366 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 7, 2022. |
| 9. This option was granted on March 10, 2023 with respect to 8,431 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 10, 2023. |
| 10. This option was granted on October 13, 2023 with respect to 3,766 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 13, 2023. |
| 11. This option was granted on March 20, 2024 with respect to 9,039 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 20, 2024. |
| 12. This option was granted on October 16, 2024 with respect to 3,766 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 16, 2024. |
| 13. This option was granted on March 14, 2025 with respect to 18,734 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 14, 2025. |
| 14. This option was granted on October 3, 2025 with respect to 6,944 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 3, 2025. |
| 15. This option was granted on March 20, 2026 with respect to 14,874 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 20, 2026. |
| 16. This restricted stock unit award was granted on March 10, 2023 with respect to 5,202 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. |
| 17. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. |
| 18. This restricted stock unit award was granted on March 20, 2024 with respect to 6,780 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. |
| 19. This restricted stock unit award was granted on December 18, 2024 with respect to 15,000 Common Shares, with 100% of the shares vesting on December 18, 2027. |
| 20. This restricted stock unit award was granted on March 14, 2025 with respect to 11,250 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. |
| 21. This restricted stock unit award was granted on December 16, 2025 with respect to 12,000 Common Shares, with 100% of the shares vesting on December 16, 2028. |
| 22. This restricted stock unit award was granted on March 20, 2026 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027, (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. |
| 23. This restricted stock unit award was granted on May 29, 2026 with respect to 10,000 Common Shares, with 100% of the shares vesting on November 29, 2028. |
| /s/ Andrew Jacob Silver | 10/21/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||